Linda B. Baughn

Geneticist and research scientist at Mayo Clinic working to better understand, diagnose and treat B-cell malignancies. Opinions on Twitter are my own.

[Linda B. Baughn @lbaughn]

@theMMRF @MMRFTeam4Cures An incredible experience. 30 miles of hiking with new friends. The best part: the team raised $75K for MM research! So grateful for the opportunity @GD_251

[Linda B. Baughn @lbaughn]

Super cool study. A good reason not to fast.

[Delgoffe Lab @DelgoffeLab]

Dearest gentle reader, we are delighted to announce a new story from our lab published in @Nature describing how a meal's systemic metabolic changes are interpreted by your immune system to enhance adaptive immunity. A thread 1/ https://t.co/zACqCLxDMU

[Linda B. Baughn @lbaughn]

@Rfonsi1 @RahulBanerjeeMD This could help 😀https://t.co/3A2jpymdUr

[Linda B. Baughn @lbaughn]

Thrilled about this collaborative project evaluating venetoclax response in the myeloma subtype I’m so curious about-t(11;14). Grateful to all of the collaborators included here.

[Francesco Maura @FrancescoMaura4]

Excited to share our first 2026 paper from the lab! In a collaboration with @MayoClinic @MSKCancerCenter @EmoryUniversity @SylvesterCancer @OsuChsd & @MSK_DeptOfMed, we investigated the drivers of venetoclax resistance in t(11;14) Multiple Myeloma #mmsm. https://t.co/hc8GMBgdq8

[Linda B. Baughn @lbaughn]

@mehndz @RahulBanerjeeMD @VincentRK @OncBrothers @BijoyTelivala @rajshekharucms @Myeloma_Doc 20% is the technical cutoff- determined by the lab. If result is < 20%, you can’t say a result is “positive”. <20% is within the “normal range” because by FISH you can random lost, gained, overlapped signals etc similar to other assays. Assay “noise.”

[Linda B. Baughn @lbaughn]

@RahulBanerjeeMD @VincentRK @OncBrothers @BijoyTelivala @rajshekharucms @Myeloma_Doc Good call Rahul. Agree likely trisomy 17. Curious if case is hyperdiploid with a possible trisomy 11 and 17 since they found gain of TP53 and CCND1. NOT tp53 del.

[Linda B. Baughn @lbaughn]

Standardizing FISH testing in myeloma is critical to reduce lab to lab variability and misinterpretation. We propose guidelines for FISH panel design and reporting to align with the new IMS/IMWG risk stratification. @CG_Consortium @MayoMyeloma

[Vincent Rajkumar @VincentRK]

Just out: Guidelines for testing and reporting cytogenetic results in myeloma @BloodCancerJnl⁩ #OpenAccess Bookmark!

Allows you to incorporate latest IMS/IMWG high risk criteria in practice.
⁦@lbaughn⁩ ⁦@RahulBanerjeeMD⁩ ⁦@Rfonsi1⁩ https://t.co/xzFgvOfpss

[Linda B. Baughn @lbaughn]

@RenoHemonc @AuclairDan Commercial labs like Mayo will be reporting mono and biallelic 1p. This information would also be in the cytogenetics nomenclature in commercial lab reports. Mono del=x1, biallelic del=x0

[Vincent Rajkumar @VincentRK]

We will also be providing recommendations to other labs on how to perform and interpret to meet the IMS/IMWG definition with a publication led by @lbaughn in @BloodCancerJnl shortly.

Stay tuned.

[Aneta Mikulasova @AnetaMikulasova]

We’re hiring!
Postdoc in Computational Genomics at @EdinUni_IGC
Focus: myeloma genome, structural variants, heterochromatin, multiomics

Deadline: 9 July 2025, 23:59 GMT

Apply here: https://t.co/zD0exFz4gi

#myeloma #postdoc #genomics #bioinformatics #epigenetics #codeandkilts

[Joachim Schork @JoachimSchork]

Visualize genomic data with ease using gggenomes, an R package that extends ggplot2 to handle and display genomic information intuitively. Whether you’re comparing genomes, analyzing features, or showcasing synteny, gggenomes provides the tools you need to turn complex genomic data into clear, informative visualizations.

Why use gggenomes?

✔️ Genomic-focused visualizations: Specifically designed for handling genomic data, including features, alignments, and comparative analysis.
✔️ Versatile and modular: Create detailed and layered plots for diverse genomic scenarios with flexibility for customization.
✔️ Built on ggplot2: Leverages ggplot2’s familiar framework, making it easy for users to adapt and enhance their visualizations.

The example visualization shown here is taken directly from the gggenomes GitHub repository, demonstrating how it transforms genomic data into compelling plots: https://t.co/FzE2wNzHeP

Curious to learn more about creating data visualizations in R and using tools like ggplot2 and its extensions? Check out my online course, "Data Visualization in R Using ggplot2 & Friends!" Take a look here for more details: https://t.co/ztlEzoEDWv

#datascienceeducation #Statistical #datastructure #RStats

[Linda B. Baughn @lbaughn]

A recently published paper supports the reporting of these unbalanced MYC-R as positive. Nice to see additional support for unbalanced MYC-R as being real abnormalities

https://t.co/FFuNYI4OQv

[Linda B. Baughn @lbaughn]

FISH testing for MYC is part of routine clinical evaluation for high grade B-cell lymphomas. We showed a high false negative rate for the MYC break apart FISH probe (4%) or the MYC/IGH probe (22%). Thus, FISH will not detect all MYC rearrangements in B-cell lymphomas.

[Linda B. Baughn @lbaughn]

We propose interpreting unbalanced MYC-r by FISH in HGBCL as “likely positive”. I hope future testing will incorporate WGS and/or RNA seq.

[Linda B. Baughn @lbaughn]

@RahulBanerjeeMD @bbehin Agree on del 17p. I would also suggest other high risk abnormalities like 1p del, 1q gain or amplification. If enough sample exists IGH break apart. If abnormal, t(4;14).

[Zohar Sachs @SachsZohar]

https://t.co/R6ZFKxoCwp

[Multiple Myeloma RF @theMMRF]

The MMRF Immune Atlas team describes immune cells & clinical outcomes in myeloma. Emory, Beth Israel, WUSTL, MSSM, Mayo & MMRF profiled >1.1 million marrow cells from CoMMpass patients. Preprint at https://t.co/xg1ac2OsYv has details. #myeloma

[Linda B. Baughn @lbaughn]

@RahulBanerjeeMD @adamssperling @alex_epi_tria *interpret

[Linda B. Baughn @lbaughn]

@RahulBanerjeeMD @adamssperling @alex_epi_tria One question is how to intercept a “relative TP53 loss” (2 copies of TP53) in the context of a trisomy 17. Is this worse than 3 copies of TP53?

[Linda B. Baughn @lbaughn]

@MyelomaAmateur @RahulBanerjeeMD @alex_epi_tria Some trisomies can be present from birth like trisomy 21. In this context however, these trisomies are acquired in the MM clone. Great questions Kate.

[Linda B. Baughn @lbaughn]

@RahulBanerjeeMD @alex_epi_tria Many labs use a probe for TP53 as well as the centromere of 17 (the middle section of the chromosome between the p and q arms).

[Linda B. Baughn @lbaughn]

We are eager to hear from the community clinicians!

[Murali Janakiram @JanakiramMurali]

We have to reach physicians in the community to see how we can get their input. Can @ACCCBuzz help to get this survey out and partnering with them.

Apart from risk stratification, can we report that BCL2 inhibitors can be used in the FISH report.
@PedalheadPHX @lbaughn

[Linda B. Baughn @lbaughn]

@PedalheadPHX @JanakiramMurali @ACCCBuzz I agree with this observation. Do clinicians want this information in a FISH report? Providing not just diagnostic or prognostic information, but information about therapeutic value?